Emtricitabine News and Research

RSS
Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
HIV drug resistance risk in mothers reduced by tenofovir/emtricitabine with nevirapine during labor

HIV drug resistance risk in mothers reduced by tenofovir/emtricitabine with nevirapine during labor

Pre-exposure prophylaxis for HIV infection

Pre-exposure prophylaxis for HIV infection

Entecavir can compromise HIV treatment

Entecavir can compromise HIV treatment

Drug warning prompts treatment changes for those infected with hepatitis B and HIV

Drug warning prompts treatment changes for those infected with hepatitis B and HIV

FDA approves Atripla for the treatment of HIV-1 infection in adults

FDA approves Atripla for the treatment of HIV-1 infection in adults

FDA approves Atripla three-drug combination tablet for treatment of HIV-1

FDA approves Atripla three-drug combination tablet for treatment of HIV-1

Approval of fixed-dose combination treatments for HIV-1 infection

Approval of fixed-dose combination treatments for HIV-1 infection

FDA approves two fixed-dose combination treatments for HIV-1 infection

FDA approves two fixed-dose combination treatments for HIV-1 infection

Plans for once-daily, fixed-dose combination of three anti-HIV drugs

Plans for once-daily, fixed-dose combination of three anti-HIV drugs